Histoplasmosis Treatment Market Size & Share, by Type (Acute, Chronic); Diagnosis (Chest CT Scan, Chest X-ray, Bronchoscopy); Drug Type (Ketoconazole, Amphotericin B, Itraconazole); Route of Administration (Oral, Intravenous) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3651
  • Published Date: Dec 04, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Histoplasmosis Treatment Market size is expected to reach USD 62 Billion by the end of 2036, growing at a CAGR of 9% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of histoplasmosis treatment was over USD 2 billion. The growth of the market can be attributed to the increasing incidences of histoplasmosis, especially amongst a few specific occupational groups. It is very common in construction workers, poultry farmers, and people with weakened immune systems. A study calculated the incidence of histoplasmosis in U.S. adults 65 years old and older at 3.4 cases for every 100,000 population.

Histoplasmosis is a relatively uncommon disease, so it can be tough to diagnose. However, as awareness of the disease increases, healthcare professionals are more likely to consider it as a potential diagnosis that can lead to earlier and more effective treatment. Therefore, growing awareness about histoplasmosis treatment among healthcare professionals as well as the population is expected to boost the market growth in the projected period.

Histoplasmosis Treatment Market
Get more information on this report: Request Free Sample PDF

Histoplasmosis Treatment Sector - Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Chronic Diseases - The histoplasmosis treatment market is expected to develop at a faster rate due to the rising incidence of cancer, and chronic lung diseases including bronchiectasis and emphysema that increase the risk of excruciating pain. The number of chronic diseases has increased, which has led to a larger rate of demand for histoplasmosis treatments globally.  In addition, it is anticipated that poor hygiene and an aging population will boost the market. 90% of Americans, according to the CDC, have histoplasmosis because the disease is frequent in humid environments. People with inadequate immunity are commonly observed to have this condition worldwide.
  • Growing Support by the Government - Market growth is projected to be driven by increased investment in high-quality health care provided by governments and state organizations. Moreover, this growth would be supplemented by an increase in the number of major companies active due to government support for the treatment of disease.
  • Increasing Demand for Pharmacotherapy – Escalating demand for pharmacotherapy for histoplasmosis in order to lower morbidity and to protect it from further complications are set to offer lucrative growth opportunities for the market players as well as for new comers into the histoplasmosis treatment market.


  • Limited Availability of Diagnostic Tests – There are currently no highly sensitive and specific diagnostic tests for histoplasmosis, which can make it difficult to diagnose the disease early and effectively. This can lead to delayed treatment and increased morbidity and mortality.
  • High Cost of Treatment is anticipated to hamper the market growth in the projected period.
  • Increasing Prevalence of Comorbidities are anticipated to Pose Restriction on the Market Expansion in the Upcoming Times. 

Histoplasmosis Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~USD 2 billion

Forecast Year Market Size (2036)

~USD 62 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Histoplasmosis Treatment Segmentation

Type (Acute, Chronic)

Based on type, the acute segment in the histoplasmosis treatment market is anticipated to garner the largest share of 60% during the projected period. The growth of this market can be attributed to the high prevalence and easy transmission of the disease. Acute histoplasmosis is more common, which is estimated to boost the segment growth. Acute histoplasmosis is more common than chronic histoplasmosis and it is estimated that 80% of cases are acute.  Furthermore, acute histoplasmosis can be easily transmitted via the inhalation of spores from infected bats or bird droppings. This ease of transmission contributes to the high incidence of this disease. Therefore, it is predicted to drive the segment growth which further might boost the market in the projected time period.

Drug Type (Ketoconazole, Amphotericin B, Itraconazole)

In terms of drug type, the amphotericin B segment is predicted to dominate the global histoplasmosis treatment market by the end of 2036. This increase can be explained by the higher use of amphotericin B for histoplasmosis treatment. The drug is recommended for pregnant women with histoplasmosis demanding immediate treatment. It is also used to treat acute progressive disseminated histoplasmosis as maintenance therapy, which in turn drives up the growth of this segment.

Our in-depth analysis of the global market includes the following segments:


  • Acute
  • Chronic


  • Chest CT Scan
  • Chest X-ray
  • Bronchoscopy

     Drug Type

  • Ketoconazole
  •  Amphotericin B
  •  Itraconazole

     Route of Administration

  • Oral
  • Intravenous

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Histoplasmosis Treatment Industry- Regional Synopsis

North American Market Forecasts

The histoplasmosis treatment market in the North America region is anticipated to gain the largest revenue share of 33% throughout the projected period. The United States is considered to be the dominant country in terms of disease growth rate and is set to be the country to expand the histoplasmosis treatment market the most. This is due to the increasing number of patients with malignant diseases and immunodeficiency.  According to the CDC, in North America histoplasmosis is the most common disease in HIV/AIDS patients, of which 4,444 and 30% of patients die due to their immunocompromised state. Additionally, an increasing research and development and technological advancements in the region are some of the driving forces for the histoplasmosis treatment market.  

European Market Statistics

The histoplasmosis treatment market in the Europe region is anticipated to hold substantial growth in the time period between 2024-2036. Increasing focus on medical facilities and increasing population aged 65 and above are expected to drive market growth. Furthermore, the demand for the histoplasmosis treatment market is increasing due to the rise in chronic diseases that weaken the human immunity of people in the region. Furthermore, the European Union also offers support for the advancement of healthcare infrastructure and improving the healthcare industry in Europe. They consecutively offer funds for the research and development of novel therapies in order to offer enhanced histoplasmosis treatment to patients in this region.

Research Nester
Histoplasmosis Treatment Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Histoplasmosis Treatment Landscape

    • Alembic Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Hindustan Antibiotics Limited
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Siemens Healthcare GmbH
    • Pfizer Inc.

In the News

  • Novartis AG to collaborate with Hewlett Packard Enterprise to address global health challenges. Novartis is the leading pharmaceutical company distributing drugs over the years.
  • Sandoz announced the acquisition of cephalosporin antibiotics business of GSK, to expand its portfolio in manufacturing antibiotics.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3651
  • Published Date: Dec 04, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of histoplasmosis and growing prevalence of chronic diseases are some of the major factors anticipated to drive the growth of the histoplasmosis treatment market.

The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2024-2036.

The major players in the market are of Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and others.

The acute segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Histoplasmosis Treatment Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying